Literature DB >> 1697721

Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes.

I N Mbawuike1, P R Wyde, P M Anderson.   

Abstract

A dose-dependent, vaccine-induced protection of aged and young Balb/c mice against lethal influenza A virus challenge has been demonstrated. Low dose formalin-inactivated influenza A virus vaccine was protective in young mice, but not in aged mice, while a higher dose was protective in both. Administration of low dose vaccine with IL-2 liposomes conferred protection comparable to the high dose in aged mice. Serum neutralizing antibody responses were stimulated by vaccine in a dose-dependent manner while IL-2 liposomes significantly enhanced responses in the low dose paralleled protection in young but not in aged mice. Lung interferon levels paralleled lung virus titres in young but not in aged mice. CTL responses in infected mice were generally higher in young than aged mice. These results demonstrate efficacy of IL-2 liposomes as an adjuvant for influenza virus vaccines in the aged.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697721     DOI: 10.1016/0264-410x(90)90093-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory.

Authors:  G Gregoriadis; Z Wang; Y Barenholz; M J Francis
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

Review 2.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

4.  Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Authors:  Christian Kittel; Boris Ferko; Martina Kurz; Regina Voglauer; Sabine Sereinig; Julia Romanova; Gabriela Stiegler; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 5.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

6.  NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.

Authors:  Natalie Pica; Ryan A Langlois; Florian Krammer; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

7.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

8.  Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Authors:  J J Bergers; W Den Otter; H F Dullens; C T Kerkvliet; D J Crommelin
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

Review 9.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity.

Authors:  Aishwarya Sridharan; Marc Esposo; Khushboo Kaushal; Jia Tay; Kathyrn Osann; Sudhanshu Agrawal; Sudhir Gupta; Anshu Agrawal
Journal:  Age (Dordr)       Date:  2010-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.